Showing results (521-530 of 1,824) with videos related to

Sort By:
Pageof 183
Signal Transduction and Targeted Therapy|March 18, 2022
Therapeutic targeting miR130b counteracts diffuse large B-cell lymphoma progression via OX40/OX40L-mediated interaction with Th17 cellsRui Sun, Pei-Pei Zhang, Xiang-Qin Weng, et al.
Signal Transduction and Targeted Therapy|April 8, 2022
Identification of the receptor of oncolytic virus M1 as a therapeutic predictor for multiple solid tumorsDeli Song, Xudong Jia, Xincheng Liu, et al.
Signal Transduction and Targeted Therapy|April 5, 2022
Targeted protein degradation: mechanisms, strategies and applicationLin Zhao, Jia Zhao, Kunhong Zhong, et al.
Signal Transduction and Targeted Therapy|March 30, 2022
Downregulation of MEIS1 mediated by ELFN1-AS1/EZH2/DNMT3a axis promotes tumorigenesis and oxaliplatin resistance in colorectal cancerYimin Li, Yaqi Gan, Jiaxin Liu, et al.
Signal Transduction and Targeted Therapy|April 1, 2022
Nuclear Aurora kinase A switches m6A reader YTHDC1 to enhance an oncogenic RNA splicing of tumor suppressor RBM4SiSi Li, YangFan Qi, JiaChuan Yu, et al.
Signal Transduction and Targeted Therapy|October 20, 2021
XBP1 regulates the protumoral function of tumor-associated macrophages in human colorectal cancerYahui Zhao, Weina Zhang, Miaomiao Huo, et al.
Signal Transduction and Targeted Therapy|March 1, 2022
Asymmetric, amphiphilic RGD conjugated phthalocyanine for targeted photodynamic therapy of triple negative breast cancerRui Li, Yiming Zhou, Yijia Liu, et al.
Signal Transduction and Targeted Therapy|March 21, 2022
The DNMT1-PAS1-PH20 axis drives breast cancer growth and metastasisYenan Fu, Xi Zhang, Xiao Liu, et al.
Signal Transduction and Targeted Therapy|March 4, 2022
Immunogenicity and protective efficacy of a recombinant protein subunit vaccine and an inactivated vaccine against SARS-CoV-2 variants in non-human primatesQian He, Qunying Mao, Xiaozhong Peng, et al.
Signal Transduction and Targeted Therapy|May 19, 2017
Analyses of publicly available genomics resources define FGF-2-expressing bladder carcinomas as EMT-prone, proliferative tumors with low mutation rates and high expression of CTLA-4, PD-1 and PD-L1Elizabeth A McNiel, Philip N Tsichlis
Pageof 183